For Pregnancies Up to Nine Weeks, Medication to Be Prescribed and Dispensed Directly by Doctors for Initial Two Years
Implementation Could Begin as Early as the First Quarter of Next Year

The government is moving forward with the official introduction of abortion medication. This comes seven years after the Constitutional Court ruled the criminalization of abortion unconstitutional in 2019. The medication will be rolled out in phases, initially targeting pregnancies up to nine weeks. For the first two years, the administration method being considered will require both prescription and dispensing by physicians within medical institutions. The earliest possible timeline for implementation is projected to be the first quarter of next year.


The Ministry of Gender Equality and Family, together with the Ministry of Health and Welfare and the Ministry of Food and Drug Safety, announced the “Plan for Introduction of Medication for Induced Abortion” at the 14th National Policy Coordination Meeting held at the Government Complex Seoul on the morning of September 16. This follows President Lee Jaemyung’s directive on July 14 for preparations to discuss the possibility of permitting abortion medication at a Cabinet meeting.


Official Introduction of Abortion Medication in Korea...7 Years After Constitutional Ruling on Abortion Ban (Comprehensive) View original image

The product under consideration for introduction is “Mifegymisojeong” by Hyundai Pharm. It is a package that sequentially administers one 200mg tablet of “mifepristone,” which blocks the action of progesterone (a hormone essential to maintaining pregnancy) and terminates pregnancy, and four 200mcg tablets of “misoprostol,” which induces uterine contractions and cervical relaxation for labor induction and postpartum hemorrhage prevention/treatment. Taking only misoprostol up to 12 weeks of pregnancy has an 80-85% success rate, but when combined with mifepristone, efficacy increases to 95%. The standard approach is to take misoprostol 1–2 days after administering mifepristone.


In Korea, the medication will be authorized for use in pregnancies up to nine weeks. According to government officials, this is because the product license application is based on clinical trial data limited to usage within nine weeks of pregnancy.


Abortion medication is already widely used worldwide. France became the first country to approve abortion drugs in 1988, followed by the United States in 2000, India in 2002, Australia in 2012, and Japan in 2023. As of 2024, about 100 countries have authorized abortion medication. The World Health Organization (WHO) has also designated medical abortion medication as essential medicine.


Won Minkyoung, Minister of Gender Equality and Family, is making an announcement on September 16, 2026, at the Government Complex Seoul in Jongno-gu, Seoul, regarding the official introduction of abortion medication. Photo by Yongjun Cho

Won Minkyoung, Minister of Gender Equality and Family, is making an announcement on September 16, 2026, at the Government Complex Seoul in Jongno-gu, Seoul, regarding the official introduction of abortion medication. Photo by Yongjun Cho

View original image

The decisive factor in accelerating this discussion was a binding interpretation from the Ministry of Government Legislation. On August 19, they determined that, even though medication is not explicitly listed as a method for artificial abortion under the Mother and Child Health Act, it is still possible to obtain regulatory approval for abortion medication. They judged that, since the period for legal abortion is not stipulated by law at present, if the medication meets the necessary standards for safety and efficacy, the Ministry of Food and Drug Safety is required to grant regulatory approval for a product that indicates induced abortion as its use. This means the Ministry cannot arbitrarily refuse approval due to a lack of abortion-related legislation. Therefore, even prior to legislative changes, if the product meets approval requirements, formal introduction is possible. This interpretation occurred because, even after the decriminalization of abortion, a legislative and regulatory vacuum persisted regarding abortion procedures.


Previously, the Constitutional Court ruled the anti-abortion law unconstitutional in April 2019. However, no follow-up legislation was enacted to stipulate permissible periods or methods for abortion, and abortion medication has not been officially approved in South Korea.


The formal introduction of abortion medication holds significant meaning for women’s health rights and their right to self-determination.


The Ministry of Gender Equality and Family stated, “The unregulated and illicit circulation of non-approved medications and substitutes is undermining safety, and women’s rights to choose between surgery and medication according to their health conditions are being restricted. With the rising socio-economic burden of abortion, such as increasing costs, the introduction of abortion medication is urgently needed.”


The Ministry of Food and Drug Safety plans to rigorously review the submitted materials, including safety, efficacy, quality, and risk management plans for abortion medications as part of the authorization process.


An official from the Ministry of Food and Drug Safety stated, “There are steps to complete in the import process, such as safety checks, quality assessments, and securing supplies by the company. If the company is sufficiently prepared and the product is introduced, we will do our best to ensure it can be available as early as the beginning of next year, within the first quarter.”


Won Minkyeong, Minister of Gender Equality and Family (right), and Oh Yukyung, Commissioner of the Ministry of Food and Drug Safety, are listening to Prime Minister Han Seongsook's remarks on abortion medication at the National Policy Coordination Meeting held at the Government Seoul Office in Jongno-gu, Seoul on September 16, 2026. Photo by Yoyongjun

Won Minkyeong, Minister of Gender Equality and Family (right), and Oh Yukyung, Commissioner of the Ministry of Food and Drug Safety, are listening to Prime Minister Han Seongsook's remarks on abortion medication at the National Policy Coordination Meeting held at the Government Seoul Office in Jongno-gu, Seoul on September 16, 2026. Photo by Yoyongjun

View original image

According to the Ministry of Food and Drug Safety, the product license application for this medication was filed in December 2024 and is currently undergoing supplementary review. Once the company submits the supplemental documentation, the Ministry will evaluate safety and efficacy before making a decision on approval. Even after regulatory approval, further steps such as product import, labeling, quality/safety tests, and securing inventory will be required. The government plans to cooperate with the manufacturer to introduce it domestically as early as the first quarter of next year.


The Ministry of Health and Welfare additionally announced that, in the initial phase, management will require direct prescription and dispensing by physicians at medical institutions for a two-year trial period, after which an incremental expansion will be reviewed following assessment of side effects and safety. This is because, although the Constitutional Court’s ruling rendered the “self-induced abortion” and “physician’s abortion” provisions in the Criminal Code ineffective, the Ministry of Justice has interpreted that pharmacists could still face criminal liability for dispensing abortion medication.



Whether the medication will be covered by the National Health Insurance will be decided later. A welfare ministry official explained, “Insurance coverage will be considered after the pharmaceutical company submits a reimbursement application. Separately, we will review whether aspects such as prior ultrasound testing can qualify for insurance reimbursement, even if this differs from the medication itself.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing